Serum salusin-α and salusin-β levels in patients with behcet’s disease

14Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Behcet’s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients. Objective: The aim of this study was to determine serum salusin-α and salusin-β levels in BD patients and healthy controls and to investigate their association with MetS. Patients and Methods: Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-α and salusin-β levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS. Results: The mean serum salusin-α level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-β level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04). Conclusions: Serum salusin-α level (an anti-atherogenic molecule)was lower, while serum salusin-β level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-α and the increase in salusin-β levels contribute to the development of MetS.

Cite

CITATION STYLE

APA

Erden, I., Demir, B., Uçak, H., Cicek, D., Dertlioğlu, S. B., & Aydin, S. (2014). Serum salusin-α and salusin-β levels in patients with behcet’s disease. European Journal of Dermatology, 24(5), 577–582. https://doi.org/10.1684/ejd.2014.2397

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free